# Cinnulin PF (Cinnamomum burmannii)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cinnulin-pf
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Cinnamomum burmannii extract, Indonesian cinnamon extract, Water-soluble cinnamon extract, Standardized cinnamon polyphenol extract, Cinnamon procyanidin extract, Type-A polymer cinnamon extract

## Overview

Cinnulin PF is a patented, water-soluble extract of Cinnamomum burmannii standardized for Type-A doubly linked procyanidin polymers, which activate insulin receptor signaling by phosphorylating the insulin receptor substrate (IRS-1) and upregulating GLUT4 transporter translocation. This mechanism enhances cellular glucose uptake and improves [insulin sensitivity](/ingredients/condition/weight-management) without requiring full insulin secretion.

## Health Benefits

• Reduces fasting blood glucose by 8.4% in prediabetic individuals over 12 weeks (moderate evidence from human trials)
• Significantly lowers HbA1c and improves β-cell function in Type 2 diabetes patients (strong evidence from 210-person RCT)
• Decreases total and [LDL cholesterol](/ingredients/condition/heart-health) at 500mg daily dosing (moderate evidence from controlled trials)
• Improves systolic blood pressure and body composition (preliminary evidence from 12-week study)
• Enhances [insulin sensitivity](/ingredients/condition/weight-management) and reduces insulin resistance (moderate evidence from multiple studies)

## Mechanism of Action

Cinnulin PF's Type-A procyanidin polymers activate insulin receptor tyrosine kinase, promoting phosphorylation of IRS-1 and downstream activation of the PI3K/Akt pathway, which drives GLUT4 vesicle translocation to the cell membrane and increases glucose uptake in skeletal muscle and adipose tissue. The extract also inhibits protein tyrosine phosphatase 1B (PTP1B), an enzyme that normally dephosphorylates and deactivates the insulin receptor, thereby prolonging insulin signaling. Additionally, Cinnulin PF has demonstrated HMG-CoA reductase inhibitory activity, partially explaining its observed reductions in [LDL cholesterol](/ingredients/condition/heart-health) at 500 mg daily doses.

## Clinical Summary

A landmark 210-participant randomized controlled trial found that 500 mg of Cinnulin PF daily significantly reduced HbA1c levels and improved β-cell function in Type 2 diabetes patients over 12 weeks, representing strong human trial evidence. A separate human trial in prediabetic individuals documented an 8.4% reduction in fasting [blood glucose](/ingredients/condition/weight-management) over the same 12-week period, categorized as moderate evidence given smaller sample sizes. At the 500 mg daily dose, statistically significant reductions in total cholesterol and [LDL cholesterol](/ingredients/condition/heart-health) have been observed in multiple trials, though lipid evidence remains secondary to glucose outcomes. Evidence is currently insufficient to recommend Cinnulin PF as a standalone diabetes treatment, and it is best characterized as an adjunctive blood sugar support compound.

## Nutritional Profile

Cinnulin PF is a patented water-soluble extract of Cinnamomum burmannii bark, standardized to contain concentrated Type-A doubly linked procyanidin polymers (polyphenolic polymers), which are the primary bioactive compounds responsible for its insulin-mimetic effects. As an extract rather than whole spice, macronutrient content is negligible per typical 250–500mg serving. Key bioactive compounds include: Type-A procyanidins (oligomeric proanthocyanidins) at standardized concentrations, cinnamaldehyde (present in reduced amounts compared to whole cinnamon due to water-based extraction process that removes fat-soluble volatile oils), and methylhydroxychalcone polymer (MHCP), which activates insulin receptor signaling pathways. The water-based extraction process specifically concentrates the water-soluble polyphenolic fraction while substantially reducing coumarin content to approximately 0.0004% or less per serving (versus up to 1% in whole Cassia cinnamon), making it significantly safer for chronic use than whole cinnamon powder. Trace minerals from the bark matrix may include manganese (~0.1–0.2mg per 500mg dose) and calcium. Bioavailability is enhanced relative to whole cinnamon because the extraction process removes insoluble fiber and lipid components that may impede polyphenol absorption; the Type-A procyanidins are partially absorbed in the small intestine with additional colonic fermentation yielding phenolic metabolites. No significant vitamin or dietary fiber content is present at standard supplemental doses.

## Dosage & Preparation

Clinically studied dosage: 250-500mg daily of Cinnulin PF standardized for polyphenolic type-A polymers. In cell culture studies, 20 µg/mL was identified as the optimal non-toxic concentration. Treatment durations in clinical trials ranged from 12 weeks to 4 months. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Cinnulin PF is generally well tolerated at doses of 250–500 mg daily, with no serious adverse events reported in clinical trials up to 12 weeks; the water-soluble extraction process removes fat-soluble coumarin, substantially reducing the liver toxicity risk associated with whole cinnamon powder. Individuals taking insulin, metformin, sulfonylureas, or other hypoglycemic agents should use Cinnulin PF cautiously, as additive blood-glucose-lowering effects may increase hypoglycemia risk and require medication adjustment under physician supervision. Pregnant and breastfeeding women should avoid Cinnulin PF due to insufficient safety data in these populations, and individuals with known hypersensitivity to Cinnamomum species should not use the extract. Those on anticoagulant therapies such as warfarin should consult a physician, as cinnamon-derived compounds may have mild antiplatelet properties that could potentiate bleeding risk.

## Scientific Research

A randomized controlled trial in 210 individuals with Type 2 diabetes showed significant reductions in fasting plasma glucose and HbA1c with 250-500mg daily of cinnamon extract over 4 months. A 12-week study in prediabetic subjects demonstrated an 8.4% decrease in fasting [blood glucose](/ingredients/condition/weight-management) with Cinnulin PF supplementation. Multiple systematic reviews and meta-analyses support cinnamon's effects on glycemic control and lipid profiles in Type 2 diabetes patients.

## Historical & Cultural Context

While the research indicates that cinnamon (Cinnamomum burmanni) has accumulated evidence of beneficial effects in type-2 diabetes which prompted commercialization of supplemental forms, specific details regarding historical traditional medicine use or which traditional medicine systems employed it are not provided in the available sources.

## Synergistic Combinations

Chromium picolinate, Alpha-lipoic acid, Berberine, Bitter melon extract, Gymnema sylvestre

## Frequently Asked Questions

### How much Cinnulin PF should I take for blood sugar support?

The most clinically studied dose of Cinnulin PF is 500 mg daily, which was used in the pivotal 210-person RCT demonstrating reductions in HbA1c and fasting glucose. Some studies have used 250 mg twice daily with comparable results. It is typically taken with meals to align with postprandial glucose metabolism.

### Is Cinnulin PF the same as regular cinnamon powder?

No — Cinnulin PF is a patented aqueous (water-soluble) extract of Cinnamomum burmannii standardized for Type-A procyanidin polymers, the bioactive compounds responsible for insulin-sensitizing effects. Unlike whole cinnamon powder, the extraction process removes fat-soluble coumarin, a compound present in Cassia-type cinnamons that can cause liver damage at high doses. This makes Cinnulin PF a safer and more concentrated option than eating cinnamon or taking non-standardized cinnamon capsules.

### How long does it take for Cinnulin PF to lower blood sugar?

Clinical trials report measurable reductions in fasting blood glucose within 12 weeks of daily use at 500 mg. The 8.4% reduction in fasting glucose observed in the prediabetic trial was recorded at the 12-week endpoint, suggesting the compound requires sustained use rather than producing acute effects. No reliable data exist on effects beyond 12 weeks of continuous supplementation.

### Can Cinnulin PF interact with metformin or insulin?

Yes, Cinnulin PF can have additive hypoglycemic effects when combined with metformin, insulin, or sulfonylureas because it independently enhances insulin receptor signaling via IRS-1 phosphorylation and GLUT4 upregulation. This combination may lower blood glucose beyond the intended therapeutic range, increasing hypoglycemia risk. Anyone taking prescription glucose-lowering medications should consult their physician before adding Cinnulin PF and monitor blood glucose more frequently during initial use.

### Does Cinnulin PF also help with cholesterol?

Yes, studies using 500 mg of Cinnulin PF daily have reported statistically significant reductions in total cholesterol and LDL cholesterol, likely due in part to partial inhibition of HMG-CoA reductase activity by its procyanidin compounds. However, the lipid-lowering evidence is secondary to its glucose research and is based on smaller trials. Cinnulin PF should not be considered a replacement for statins or other lipid-lowering therapies.

### What clinical evidence supports Cinnulin PF's effectiveness for blood sugar control?

Cinnulin PF has strong evidence from a 210-person randomized controlled trial showing significant reductions in HbA1c and improvements in β-cell function in Type 2 diabetes patients. Additional moderate-quality evidence demonstrates an 8.4% reduction in fasting blood glucose over 12 weeks in prediabetic individuals. These human trials provide substantially more robust evidence than typical cinnamon powder studies, making Cinnulin PF one of the better-researched cinnamon extracts for metabolic health.

### Who should consider taking Cinnulin PF, and who should avoid it?

Cinnulin PF is particularly beneficial for individuals with prediabetes, Type 2 diabetes, or metabolic syndrome seeking additional blood sugar and cholesterol support. Those already on blood sugar-lowering medications or insulin should consult a healthcare provider before supplementing, as it may potentiate these effects. Pregnant and nursing women should avoid Cinnulin PF due to insufficient safety data in these populations.

### How does the proprietary extraction process of Cinnulin PF affect its potency compared to regular cinnamon?

Cinnulin PF uses a standardized, water-soluble extraction process from Cinnamomum burmannii bark that concentrates bioactive compounds responsible for blood sugar benefits, unlike regular cinnamon powder which contains highly variable active ingredient levels. This standardization allows for consistent dosing and predictable clinical outcomes, which is why research studies specifically use Cinnulin PF rather than common cinnamon. The extraction method also improves bioavailability of key polyphenols, making smaller doses potentially more effective than larger amounts of whole cinnamon powder.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*